Nutrabiotech AG-881 98% 1G Powder, high purity Vorasidenib AG-881 powder, dual mutant IDH1/IDH2 inhibitor, brain penetrant 2-HG blocker, IDH-mutant glioma tumor research raw material

Vorasidenib CAS 1644545-52-7 98% Purity IDH1/IDH2 Inhibitor Powder

High purity Vorasidenib powder CAS 1644545-52-7 with 98% HPLC purity. Brand name VORANIGO, potent dual IDH1/IDH2 inhibitor for glioma and oncology research, factory bulk supply, full certificates and fast global delivery.
Category: Tags: , , , , , , , ,
Vorasidenib AG-881 (CAS 1644545-52-7) Dual Mutant IDH1/IDH2 Inhibitor | Glioma Research

Vorasidenib CAS 1644545-52-7
Brain-Penetrant Dual Mutant IDH1/IDH2 Inhibitor (Glioma)

Vorasidenib (CAS 1644545-52-7), also AG-881, is a brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (mIDH1/mIDH2). It blocks the neomorphic activity producing the oncometabolite 2-hydroxyglutarate (2-HG), reversing epigenetic silencing and slowing growth of IDH-mutant gliomas and other tumors. Formula C14H13ClF6N6, MW 414.74. Research-grade with COA.

IDH InhibitorMutant IDH1/IDH2VorasidenibAG-881Glioma2-HGEpigeneticOncology
Request a Quote Technical Specs
414.74
MW (C14H13ClF6N6)
≥98%
Purity (HPLC)
mIDH1/2
Oncometabolite block

Molecular Information

Name: Vorasidenib (AG-881)
CAS: 1644545-52-7
Formula: C14H13ClF6N6
MW: 414.74 g/mol
Class: Mutant IDH1/IDH2 inhibitor
Core: Chloropyridinyl bis(trifluoropropyl)triazine
Target: Mutant IDH1 / IDH2
Activity: Blocks 2-HG production
MP: Not firmly reported
Appearance: White to off-white powder
Synonyms: AG-881
Storage: -20°C, protect from light
1644545-52-7
🧪
CAS Number
414.74
⚖️
Molecular Weight
Mutant IDH1/IDH2 Inhibitor
🎯
Primary Activity
≥98%
✅
Purity

Product Technical Specifications

Complete physicochemical properties and QC parameters for Vorasidenib (CAS 1644545-52-7)

📋 Physicochemical Properties

  • Product NameVorasidenib (AG-881)
  • IUPAC Name6-(6-chloro-2-pyridinyl)-2-N,4-N-bis[(2R)-1,1,1-trifluoropropan-2-yl]-1,3,5-triazine-2,4-diamine
  • CAS Number1644545-52-7
  • SynonymsVorasidenib; AG-881
  • Molecular FormulaC14H13ClF6N6
  • Molecular Weight414.74 g/mol
  • SourceSynthetic IDH inhibitor
  • AppearanceWhite to off-white powder
  • Water SolubilityLow
  • Organic SolubilityDMSO; some aqueous buffers
  • Compound ClassMutant IDH1/IDH2 inhibitor / oncology
  • HS Code2934.99

🔬 Quality Control & Handling

  • Purity (HPLC)≥98%
  • FormCrystalline powder
  • Primary TargetMutant IDH1 / IDH2
  • Assay Readout2-HG levels; epigenetic marks
  • SelectivityDual mIDH1/mIDH2; brain-penetrant
  • Storage Condition-20°C, sealed, protect from light
  • Solution StabilityDMSO stock stable weeks at -20°C
  • ShippingCold chain recommended
  • QC DocumentationCOA / HPLC / NMR / MS / MSDS
  • Pack Sizes100mg / 500mg / 1g / 5g / 10g
  • Stock StatusIn Stock
  • Use StatementResearch / investigational; not for human use

Key Molecular Targets & Pathway Nodes

Vorasidenib engages the molecular machinery and pathway nodes that define its research utility.

🧬 Mutant IDH1 🧬 Mutant IDH2 🧪 2-HG (oncometabolite) 🧪 Epigenetic reprogramming 🧭 Glioma cells 🧬 NADPH / metabolism 🦴 Tumor growth 🔬 IDH inhibitor profiling 💧 DNA methylation 🧭 CNS tumors

How Vorasidenib Works: Starving the Oncometabolite

Vorasidenib blocks mutant IDH, cutting off 2-HG and reversing epigenetic silencing

1

Inhibition of Mutant IDH1 / IDH2

Vorasidenib is a brain-penetrant dual inhibitor of the neomorphic mutant isocitrate dehydrogenase 1 and 2 enzymes found in gliomas and other tumors.

2

Suppression of 2-HG Production

Mutant IDH aberrantly converts α-ketoglutarate to the oncometabolite 2-hydroxyglutarate (2-HG); vorasidenib blocks this, lowering intracellular 2-HG.

3

Epigenetic Reset & Growth Arrest

Reduced 2-HG relieves competitive inhibition of α-KG-dependent enzymes (DNA/histone demethylases), reversing aberrant epigenetic silencing and slowing IDH-mutant tumor growth.

⚖️ Vorasidenib vs Comparators

  • Vorasidenib (this product)Dual mIDH1/mIDH2; brain-penetrant
  • IvosidenibMutant IDH1-selective
  • EnasidenibMutant IDH2-selective
  • Selective EdgeCovers both IDH1 & IDH2 mutations
  • Research NicheIDH-mutant glioma & CNS tumors

♻️ Downstream Biological Consequences

  • EnzymemIDH1/2 inhibited
  • Metabolite2-HG falls
  • EpigeneticsDNA/histone demethylation restored
  • DifferentiationBlocks blocked differentiation
  • TumorGrowth slowed
  • CNSBrain penetration achieved

Research Applications & Models

Vorasidenib is the reference dual mutant-IDH inhibitor for glioma and epigenetic research.

🧭

IDH-Mutant Glioma Research

Foundational dual mIDH1/mIDH2 agent for low-grade glioma models.

Glioma
💧

2-HG / D-2-HG Studies

Measures oncometabolite suppression directly.

2-HG
🧪

Epigenetic (Methylation) Models

Probes DNA/histone demethylase recovery.

Epigenetic
🧭

CNS Tumor Studies

Brain-penetrant profiling in intracranial models.

CNS
🔬

Mutant-IDH Profiling

Compared with ivosidenib/enasidenib.

Profiling
🦴

Differentiation Research

Studies blocked differentiation rescue.

Differentiation

Key Literature & Landmark Publications

Landmark work on mutant IDH inhibitors and glioma therapy.

Investigator reports. Vorasidenib (AG-881) dual mIDH1/mIDH2 inhibition.
Landmark reference
Clinical literature. Vorasidenib in IDH-mutant low-grade glioma.
Landmark reference
Review. Mutant IDH and the 2-HG oncometabolite.
Landmark reference
Preclinical reports. Vorasidenib brain penetration & epigenetics.
Landmark reference
Structure-activity literature. Dual IDH inhibitor optimization.
Landmark reference

Available Sizes & Ordering

Research-grade Vorasidenib / AG-881 (CAS 1644545-52-7) with full QC documentation; standard packs and bulk custom quantities supported.

TierPack SizeStock StatusSuitable ForLead Time
Standard100mgIn StockIDH / oncology assaysSame/next-day ship
Medium500mgIn StockCell & 2-HG studiesSame/next-day ship
Large1gIn StockIn vivo glioma modelsSame/next-day ship
Bulk5gIn StockScreening & formulationQuote to confirm
Industrial10g+Made to orderProcess developmentBatch delivery

💡 Reference sizes shown above; for exact pricing and availability please contact us for a quote. Bulk orders qualify for tiered discounts.

Frequently Asked Questions (FAQ)

What is vorasidenib and what does it inhibit?
Vorasidenib (CAS 1644545-52-7), also AG-881, is a brain-penetrant dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (mIDH1/mIDH2) that blocks production of the oncometabolite 2-hydroxyglutarate. Formula C14H13ClF6N6, MW 414.74.
How is vorasidenib different from ivosidenib?
Ivosidenib is selective for mutant IDH1, while vorasidenib inhibits both mutant IDH1 and IDH2 — useful when the specific IDH mutation is unknown or both are relevant.
Why does blocking mutant IDH matter?
Mutant IDH makes 2-HG, which hijacks α-KG-dependent enzymes and silences differentiation genes; inhibiting it reverses that epigenetic block and slows tumor growth.
What readouts confirm activity?
Measurement of 2-HG (LC-MS), mutant-IDH enzyme assays, and epigenetic (DNA methylation / histone) and differentiation markers.
How soluble is vorasidenib and how should it be prepared?
It is soluble in DMSO and some aqueous buffers; poorly in water. Prepare a DMSO stock, dilute into medium (final DMSO ≤0.1% v/v), and store at -20°C protected from light.
Is QC documentation provided?
Every batch ships with a Certificate of Analysis (COA) including HPLC purity, NMR structural confirmation and MS data; MSDS/SDS and Certificates of Origin are available on request.

Need Vorasidenib for Your Research?

Research-grade Vorasidenib (CAS 1644545-52-7) — purity ≥98% HPLC, COA included
Mutant IDH1/IDH2 Inhibitor — request a quote today

Request a Quote →

Related products